Nanosonics Limited · ASX:NAN
Nanosonics — Investor Presentation (February 2010)
13 slides from Nanosonics's investor presentation, February 2010
Slide 1: Nanosonics Limited (ASX:NAN) Investor Briefing Presentation
Nanosonics Limited (ASX:NAN) Investor Briefing Presentation
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs o
Slide 3: Key Milestones 1H-FY2010
Key Milestones 1H-FY2010 • TUV and TGA audits successfully completed • Enthusiastic reception MEDICA and WFUMB conferences • FDA application progressing • Advanced discussion with US distributors and OEMs • AU$ 15.6M capital raising • Establishment of infrastructure to support EU roll-out • In-princ
Slide 4: Key drivers for shareholder value
Key drivers for shareholder value Global regulatory • Global revolution occurring to high-level disinfection environment driving • Regulators supportive of Trophon EPR demand Global acceptance of • Global infection control awareness driving growth Trophon EPR opportunities • Endorsement from OEMs, d
Slide 5: Trophon Sales
Trophon Sales Region Market drivers Reg. Market Launch opp. ANZ • HLD recommended in-between TGA approval AU$40m Mar 2009 patients • Re-orders received • In-principle 200 unit order • Trophon installed at all district health boards in Auckland region France • National move banning glutaraldehydes CE
Slide 6: Financials
Financials Category Date Amount Total shares on issue @ 12 Feb 2010 225 million Share price @ 12 Feb 2010 A$ 0.57 Market capitalisation @ 12Feb 2010 A$ 128 million Average trading volume @ 12 Feb 2010 300,000 shares per day Cash on hand @ 31 Dec 2009 A$ 21.3 million Operating expenses @ 31 Dec 2009
Slide 7: Financial results 1H-FY10
Financial results 1H-FY10 Dec 09 Dec 08 Operating income Sales 566 - Less Cost of Sales (213) - Gross profit 353 - Government grants received - - Interest income 249 817 Operating income 602 817 Expenses Operating expenses (4,754) (5,146) Operating loss before tax (4,152) (4,329) Cash assets Cash an
Slide 8: The Trophon EPR
The Trophon EPR
Slide 9: The Trophon EPR Building to meet demand
The Trophon EPR Building to meet demand Current Manufacturing facility in Alexandria Contract Manufacture Single shift capacity Sydney of 2,000 p.a. Capacity = 8,000 p.a. Move to custom Nanosonics site to increase capacity and R&D capabilities Local production anticipated to support ANZ/EU roll-out
Slide 10: The Trophon EPR Preparing for global roll-out
The Trophon EPR Preparing for global roll-out Customer Experience • Extensive field experience • Pricing & marketing validated and confirmed • Service and support systems validated and confirmed CY2010 • Expanding production capacity • Ramping up international sales, marketing and support activities
Slide 11: The Trophon EPR Commercialisation schedule CY 2010
The Trophon EPR Commercialisation schedule CY 2010 Region Status update Market preparation / Initial sales activities France Initial commercial release. • KOL endorsement Increase sales 2H-FY10 • Targeting medical Germany On track for 2H-FY10 journals UK On track for 2H-FY10 • PR activities increasi
Slide 12: Business priorities 2H-FY10
Business priorities 2H-FY10 2H-FY10 • Achievement of key commercial milestones in ANZ • Launch of product into further European countries • Appointment of US distributor • Preparation for US launch (pending FDA approval) FDA • Review proceeding within expected internal timelines 1H-FY11 • File appli
Slide 13: Slide 13